UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas

Haematologica (Roma), 2022-01, Vol.107 (1), p.201-210

2022

Volltextzugriff (PDF)

Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series

British journal of haematology, 2015-11, Vol.171 (4), p.491-500

2015

Volltextzugriff (PDF)

P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST‐HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e6843062-n/a

2023

Volltextzugriff (PDF)

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

Clinical cancer research, 2015-10, Vol.21 (20), p.4663-4675

2015

Volltextzugriff (PDF)

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Blood, 2019-11, Vol.134 (Supplement_1), p.2909-2909

2019

Volltextzugriff (PDF)

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Therapeutic Advances in Hematology, 2015-08, Vol.6 (4), p.202-208

2015

Volltextzugriff (PDF)

Hypereosinophilic syndrome presenting as thrombotic microangiopathy – a case report

Pathology, 2019-02, Vol.51, p.S122-S122

2019

Volltextzugriff (PDF)

Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia

Methods (San Diego, Calif.), 2018-02, Vol.134-135, p.32-40

2018

Volltextzugriff (PDF)

Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice

Clinical cancer research, 2014-10, Vol.20 (20), p.5240-5254

2014

Volltextzugriff (PDF)

Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG

British journal of haematology, 2017-12, Vol.179 (5), p.856-857

2017

Volltextzugriff (PDF)

Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e564-e567

2019

Volltextzugriff (PDF)

A unique case of splenic rupture secondary to vaccine‐induced immune thrombocytopenia managed with splenic embolization

ANZ journal of surgery, 2022-07, Vol.92 (7-8), p.1949-1951

2022

Volltextzugriff (PDF)

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia

American journal of clinical pathology, 2019-11, Vol.152 (6), p.818-827

2019

Volltextzugriff (PDF)

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia: A Case Series and Review of the Literature

American journal of clinical pathology, 2019-12, Vol.152 (6), p.818-827

2019

Volltextzugriff (PDF)

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Blood, 2019-11, Vol.134 (Supplement_1), p.1571-1571

2019

Volltextzugriff (PDF)

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.4030-4030

2019

Volltextzugriff (PDF)

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.19-20

2020

Volltextzugriff (PDF)

Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation

Australasian journal of dermatology, 2021-08, Vol.62 (3), p.e400-e403

2021

Volltextzugriff (PDF)

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

Blood, 2017-12, Vol.130, p.1524-1524

2017

Volltextzugriff (PDF)

Variation in outpatient consultant physician fees in Australia by specialty and state and territory

Medical journal of Australia, 2017-08, Vol.207 (4), p.179-179

2017

Volltextzugriff (PDF)

Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Internal medicine journal, 2022-10, Vol.52 (10), p.1806-1817

2022

Volltextzugriff (PDF)

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Leukemia & lymphoma, 2021-01, Vol.62 (2), p.330-336

2021

Volltextzugriff (PDF)

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT024-CT024

2023

Volltextzugriff (PDF)

Mycosis fungoides and Sézary syndrome: Australian clinical practice statement

Australasian journal of dermatology, 2021-02, Vol.62 (1), p.e8-e18

2021

Volltextzugriff (PDF)

Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia

Leukemia & lymphoma, 2019-12, Vol.60 (14), p.3417-3425

2019

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas

Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series

P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST‐HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Hypereosinophilic syndrome presenting as thrombotic microangiopathy – a case report

Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia

Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice

Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG

Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review

A unique case of splenic rupture secondary to vaccine‐induced immune thrombocytopenia managed with splenic embolization

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia: A Case Series and Review of the Literature

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

Variation in outpatient consultant physician fees in Australia by specialty and state and territory

Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Mycosis fungoides and Sézary syndrome: Australian clinical practice statement

Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia

Suchergebnisse filtern